In four patients with hemophilia, or von Willebrand's disease, intensive infusion therapy with lyophilized plasma, cryoprecipitate, (Courtland Laboratories), a commercial preparation of fibrinogen and antihemophilic globulin (Fibro-AHF), or antihemophilic globulin (Hemofil) produced hemolysis. The recipients were of blood group A or AB. These materials contained the naturally occurring isoantibodies to A and B erythrocyte antigens. Hemolysis was noted only with intensive replacement therapy. Type-specific cryoprecipitate should be given when prolonged infusion therapy is required following surgical procedures.
Seeler RA. Hemolysis Due to Anti-A and Anti-B in Factor VIII Preparations. Arch Intern Med. 1972;130(1):101–103. doi:10.1001/archinte.1972.03650010087016
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: